Question
A 6-year-old child presents with 5 days of high fever, conjunctival injection, red cracked lips, and a polymorphous rash. You are considering conditions where intravenous immunoglobulin (IVIG) is most effective as a key treatment. In which of the following conditions is IVIG most beneficial?
A. Thyroid-associated orbitopathy
B. Kawasaki syndrome
C. Inclusion body myopathy
D. Demyelinating CNS disease
E. Chronic inflammatory joint disease
Answer:
B. Kawasaki syndrome
Detailed Explanation:
IVIG is a pooled preparation of IgG antibodies derived from thousands of donors, exerting immunomodulatory effects rather than simple replacement.
In Kawasaki disease, IVIG is first-line and life-saving. This acute medium-vessel vasculitis primarily affects children and carries a significant risk of coronary artery aneurysms. Early IVIG (within 10 days of illness onset) reduces coronary complications dramatically by suppressing the intense inflammatory response.
Why others are incorrect:
- Graves’ ophthalmopathy
Managed mainly with steroids, radiotherapy, or decompression. IVIG only rarely used in refractory cases. - Inclusion body myositis
Poor response to immunotherapy; IVIG generally ineffective. - Multiple sclerosis
Disease-modifying therapies preferred; IVIG is not standard (limited niche use). - Rheumatoid arthritis
Treated with DMARDs and biologics; IVIG not routine.
Cheat Sheet (Exam-Oriented)
High-yield IVIG indications:
- Kawasaki disease
- Guillain-Barré syndrome
- Myasthenia gravis (crisis)
- ITP
- CIDP
- Dermatomyositis
- Primary immunodeficiency
Mechanism:
- Neutralizes autoantibodies
- Modulates Fc receptors
- Suppresses cytokines
Kawasaki key points:
- Fever >5 days + mucocutaneous features
- Risk → coronary aneurysm
- Treatment → IVIG + aspirin
Flash Cards
Q1: What is the most important treatment to prevent coronary aneurysms in Kawasaki disease?
A: IVIG
Q2: When should IVIG be given in Kawasaki disease?
A: Within 10 days of onset
Q3: Name a neuromuscular condition where IVIG is effective.
A: Guillain-Barré syndrome
Q4: Does inclusion body myositis respond well to IVIG?
A: No
Q5: Main mechanism of IVIG?
A: Immunomodulation (neutralizing autoantibodies, cytokine suppression)
MCQs (Advanced Level)
MCQ 1
Which of the following is the primary mechanism of IVIG in autoimmune diseases?
A. Direct pathogen killing
B. Complement activation
C. Neutralization of autoantibodies and Fc receptor modulation
D. Increased neutrophil chemotaxis
E. T-cell clonal expansion
Answer: C
Explanation: IVIG works mainly via immunomodulation—blocking Fc receptors and neutralizing pathogenic antibodies.
MCQ 2
Which of the following conditions shows the most dramatic reduction in vascular complications with IVIG?
A. Rheumatoid arthritis
B. Multiple sclerosis
C. Kawasaki disease
D. Graves ophthalmopathy
E. Inclusion body myositis
Answer: C
Explanation: IVIG reduces coronary aneurysm risk in Kawasaki disease significantly.
MCQ 3 (False statement)
Regarding IVIG, which statement is false?
A. Derived from pooled donor plasma
B. Half-life is about 3 weeks
C. It is first-line for rheumatoid arthritis
D. Used in Guillain-Barré syndrome
E. Used in primary immunodeficiency
Answer: C
Explanation: IVIG is not first-line for RA; DMARDs are.
MCQ 4
A child with fever, strawberry tongue, and conjunctivitis is at risk of which complication if untreated?
A. Renal failure
B. Coronary artery aneurysm
C. Pulmonary fibrosis
D. Liver cirrhosis
E. Myocardial infarction
Answer: B
Explanation: Classic Kawasaki complication—prevented by IVIG.
MCQ 5
Which condition is least likely to benefit from IVIG?
A. Guillain-Barré syndrome
B. CIDP
C. Kawasaki disease
D. Inclusion body myositis
E. Myasthenic crisis
Answer: D
Explanation: IBM has poor response to immunotherapy.
Summary for Quick Exam Revision
IVIG is a pooled IgG preparation with strong immunomodulatory effects and is highly effective in select autoimmune and inflammatory conditions. The most exam-relevant indication is Kawasaki disease, where early IVIG administration within 10 days significantly reduces the risk of coronary artery aneurysms. Other important uses include Guillain-Barré syndrome, myasthenic crisis, ITP, CIDP, dermatomyositis, and immunodeficiency states. It is not routinely used in conditions like rheumatoid arthritis, multiple sclerosis, or inclusion body myositis due to limited efficacy. Mechanistically, IVIG acts by neutralizing autoantibodies, modulating Fc receptors, and suppressing inflammatory cytokines. In exams, any pediatric vasculitis with mucocutaneous signs should immediately trigger Kawasaki disease and IVIG as the treatment of choice.